| Name | Title | Contact Details |
|---|
Comphealth Associates is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Wright Medical Group N.V. is a global medical device company focused on providing extremity and biologic solutions that enable clinicians to alleviate pain and restore their patients` lifestyles. The company is a recognized leader of surgical solutions for the upper extremity (shoulder, elbow, wrist and hand), lower extremity (foot and ankle) and biologics markets, three of the fastest growing segments in orthopaedics.
Manet Community Health Center is a non-profit health and social services provider that offers a range of medical and support services to South Shore residents.
Wellbiz Brands, Inc. is the nation`s premiere franchisor of wellness, fitness and beauty brands. With more than 600 locations, WellBiz Brands is uniquely qualified to serve the growing needs of the health and beauty conscious consumer through recurring revenue experience-based brands including Elements Massage®, Amazing Lash Studio® and Fitness Together®. Backed by a management team with nearly a century of combined leadership experience, WellBiz Brands accelerates scalable and predictable revenue growth by providing a robust platform of shared services, infrastructure and support. The company claimed three spots on the 2018 Inc. 5000 Fastest Growing Companies list and is headquartered in Englewood, Colorado.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.